Marc Le Bozec joins CYTOO as Chief Executive Officer
Marc Le Bozec, who has been a major stakeholder in industrial and academic biotechnologies in France for more than 15 years joins CYTOO as Chief Executive Officer.
For several years, he worked as a consultant in organization (Bossard Consultants) and in strategy (Arthur D. Little). He founded BioProtein Technologies and managed it for 8 years. He then joined Alfact Innovation as Chief Operating Officer, and contributed to the launch of a clinical trial for liver diseases. He then joined Cellectis, and made it grow from a promising start-up to a European leader in many fields. He was Chief Financial Officer and Chief Executive Officer of the Cellectis bioresearch subsidiary.
Concurrently, Marc Le Bozec serves the community and is notably member of the Scientific Advisory Board at the Inserm in France (National Institute of Health and Medical Research) since 2008, and is currently part of initiatives such as ATIP-Avenir. Marc Le Bozec graduated from HEC School of Management.
Olivier Pasquier joins CYTOO as Chief Commercial Officer
CYTOO is delighted to announce that Olivier Pasquier has joined the team as Chief Commercial Officer.
Olivier Pasquier first graduated from the French University Nice-Sophia Antipolis in molecular biology. He then completed his background with a marketing MBA from ESCP Europe.
Former Senior Marketing Manager Europe at QIAGEN, with more than 10 years experience in biology and biotechnology, he is passionate about biotech breakthroughs. He joins the team to lead the commercial success of CYTOO's 2D+ Cell Culture Platform and develop new markets in cell based assays and screening.
CYTOO’s adhesive micropatterns are mentioned in more than 30 scientific papers
CYTOO is proud to announce that its adhesive micropatterns are mentioned in more than 30 publications, covering a wide range of research areas, and in prestigious journals such as Nature, Plos One, Developmental Cell and Journal of Cell Biology. Two thesis mentioning CYTOO’s technology have also been defended.
Among major publications, some breakthroughs can be highlighted:
These papers have been published in journals with 9.903 average Impact Factor, and have been cited 14 times on average. The most cited article is Sirio Dupont's "Role of YAP/TAZ in mechanotransduction", with 141 citations.
CYTOO sponsors the Motility subgroup at the Biophysical Society meeting (Feb 02-06, Philadelphia)
CYTOO will attend the Biophysical Society (BPS) 57th Annual Meeting in Philadelphia, Pennsylvania, USA to present its innovative Cell Culture Platform, based on adhesive micropatterns. After the recent launch of the CYTOOplates Motility, specifically designed to study cell migration for screening applications in both oncology and drug discovery, the company has the great pleasure to sponsor the Motility subgroup.
CYTOO's 2D+ Technology and Institut Curie’s Organelle Map in the limelight at SLAS 2013 (Jan 12-16, Orlando)
CYTOO will attend the Society for Laboratory Automation and Screening (SLAS) 2013 conference in Orlando, Florida, USA, to present the 2D+ Solutions, opening fresh perspectives for cell based assay development in drug discovery.
A $10,000 cash prize will be attributed during SLAS 2013, and recognizes extraordinary achievement in innovative laboratory science and technology. Kristine Schauer’s Organelle Map figures among the nine 2013 SLAS Innovation Award finalists. Kristine Schauer, from the Institut Curie in Paris, France, used the crossbow adhesive micropatterns to get reproducible shape and distribution of intracellular compartments and developed a mathematical algorithm to generate and compare probabilistic density maps of the different endosome compartments. This innovative approach is a powerful universal method to identify statistically relevant hits and drug effects in complex cell based assays.
CYTOO launches 2D+ Solutions at High Content Analysis (HCA), January 08-11, 2013
CYTOO will launch the 2D+ Solutions at the High Content Analysis (HCA) Annual Meeting in San Francisco, USA.
2D+ Solutions opens fresh perspectives for cell based assay development in drug discovery.
CYTOO’s Custom Solutions bring expertise, resources and technology to address current bottlenecks in cell based assay development and screening.